BTLA/B-andT-lymphocyte attenuator/CD272 (Fc fusion) | E21-D06

BTLA/B-andT-lymphocyte attenuator/CD272 (Fc fusion) | E21-D06 | Gentaur UK, US & Europe Distribution

Short Description: Recombinant Human B- and T-Lymphocyte Attenuator is produced by our Mammalian expression system and the target gene encoding Lys31-Leu150 is expressed with a Fc tag at the C-terminus.

Shipping: Ambient

Formulation: Lyophilized from a 0.2 m filtered solution of 20mM PB, 150mM NaCl, pH7.4.

Storage: Lyophilized protein should be stored at < -20C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20C for 3 months.

Reconstitution: Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 g /ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

Purity: Greater than 95% as determined by reducing SDS-PAGE.

Endotoxin: Less than 0.1 ng/g (1 IEU/g) as determined by LAL test.

Background: B- and T-Lymphocyte Attenuator (BTLA) is a single-pass type I membrane protein containing 1 Ig-like V-type (immunoglobulin-like) domain. BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4. However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R) , not just the B7 family of cell surface receptors. BTLA is a lymphocyte inhibitory receptor that inhibits lymphocytes during immune response. BTLA also is a ligand for tumor necrosis factor (receptor) superfamily, member 14 (TNFRSF14) , also known as herpes virus entry mediator (HVEM) . BTLA-HVEM complexes negatively regulate T-cell immune responses.

Species: Human

Expression System: Human cells